Crowdonomics
All companies
VITA IMAGING logo

VITA IMAGING

Operating

Vita Imaging Inc.

Healthcare · San Jose, CA · Founded 2019

Cutting-edge cancer detection and diagnostic technology

Post-money valuation ⓘ
$40.6M
As of Sep 2026 · from Reg CF Offering (2026) · pre-money + amount raised, not a traded price
Total raised
$4,977,365
Crowd $1.9M · Private $3.1M · 8 rounds since 2020
Latest share price
$5.70
Reg CF · Common Stock · Jul 2026 offering price

Financials

FY2021–FY2025 · from SEC filings · hover any figure for its source
$0
−$1.1M
2021
$0
−$838K
2022
$0
−$1.6M
2023
$0
−$1.1M
2024
$0
−$1.8M
2025
RevenueNet income — beside revenue when positive, below the line when a loss
Metric
FY2021 audited*
FY2022 audited
FY2023 audited
FY2024 audited
FY2025 audited
Income statement
Revenue
$0
$0
$0
$0
$0
Cost of goods sold
$0
$0
$0
$0
$0
Net income
-$1,112,284
-$837,822
-$1,624,936
-$1,106,278
-$1,836,387
Taxes paid
$0
$0
$0
$0
$0
Balance sheet
Cash
$88,069
$46,568
$121,086
$32,261
$36,257
Accounts receivable
$52,589
$0
$0
$0
$0
Total assets
$306,849
$330,089
$534,788
$583,376
$607,842
Short-term debt
$206,077
$294,502
$1,709,273
$660,161
$1,106,215
Long-term debt
$623,313
$662,297
$0
$1,575,766
$2,124,036
Total liabilities
$829,390
$956,799
$1,709,273
$2,235,927
$3,230,251
Other
Headcount
—
14
14
14
10

Figures as reported by the issuer in the filing shown on hover. Each year’s pill shows the assurance level of its filed statements — audited, reviewed (CPA review, less than an audit), or unaudited, as the filing’s own report or certification states it. A dashed pill marked * is inferred instead: the SEC minimum for an offering that size, which the issuer may have exceeded. No pill means we couldn’t tell. Headcount is the filing’s point-in-time count, not a year-end average. Manually corrected figures are marked “Corrected”.

Valuation over rounds

Pre-money — the valuation set before each round’s money came in
$39.9M
pre-money
$5.7M
est. pre-money
$41.3M
pre-money
$42.5M
pre-money
$5.7M
est. pre-money
$40.6M
pre-money
Reg CF · Common · May 2023
Reg CF · Common · Feb 2024
Reg CF · Common · Aug 2024
Reg CF · Common · Jul 2025
Reg CF · Preferred · May 2025
Reg CF · Common · Jul 2026

Blue bars are the pre-money valuation the company stated for a priced round. Dotted grey bars are our estimate for rounds that didn't state one: the round's share price × the shares outstanding in its filings. Same measure as blue, but rougher.

Share price over rounds

$5.70$2.85$2.00
Jan 2020Jul 2026
Round offering price or verified disclosed saleDisclosed sale, unverified or year-only

Disclosed sales come from the issuer's own filings (prior-offering lines, audited-statement notes) and are amount ÷ securities sold. A down round is a firm point more than 25 % below the previous firm point of the same share class on a comparable basis; the comparison ignores unverified and year-only lines.

Cap table

Share counts as of Dec 31, 2025
Series A preferred stock · 49.2%Common stock · 50.8%
ClassOutstandingVotes / shareShare of totalLast price
Series A preferred stockpreferred(as of Dec 31, 2024)6,321,179149.2%$5.70Jul 2026
Common stock6,520,359150.8%—
Total12,841,538100%

Shares outstanding over timein today's share terms

13M6.4M0
Dec 2021Dec 2025
Common stockSeries A preferred stockRound opened

Changes in named holdersshares in today's terms · % of all shares at the time

Principal holders% as the filing states it, Jul 13, 2026

  • Thinh Tran1,202,795 Series A Preferred Stock12.1%of votes

Sold to the crowd

From the company's SEC filings: share counts per class, each class's voting and conversion terms, and the holders of 20% or more that Form C requires (officers and 10%+ holders on Form 1-A). Filings name only large holders, so most owners — including crowd investors — are not listed, and a holder's percentage may be of its own class rather than of the whole company. Prices and crowd share counts are in today's share terms — adjusted for splits and conversions since they were sold. Hover a figure for its filing.

Fundraising history

Reg CF · Common Stock · Jul 2026Withdrawnvia Highlander (formerly PicMii)
Raised $4.6K / $3.8MPost-money $40.6M
Raised $0 / $1.8MEst. pre-money $5.7M
Raised $330.6K / $4.1MInvestors 238Post-money $42.9M
Raised $815.6K / $3.8MInvestors 323Post-money $42.1M
Raised $359.7K / $4.1MEst. pre-money $5.7M
Raised $360.9K / $5MInvestors 582Post-money $40.8M

Team

3 people
Thinh Tran
CEO & Chairman

Mr. Tran was the Founder, CEO, & Chairman of V-Silicon, a leader in the Smart TV market delivering best in class picture and audio quality. He was previously the Founder, Chairman, & CEO of Sigma Designs since its inception in 1982 which he built from a humble start-up a publicly traded NASDAQ company, at one point was valued at two billion dollars in 2007, before leaving in 2018. Thinh also has extensive experience raising capital, exceeding M&A transactions, and providing guidance to many start-ups. Prior to Sigma Designs, Mr. Tran was employed by Amdahl Corporation and Trilogy Systems Corporation. Thinh holds a B.S.E.E. from the University of Wisconsin & M.S.E.E. from Stanford University.

Dzung Kim Tran Wright
CFO

Ms. Wright is the Chief Financial Officer of Vita Imaging, Inc. She has over 30 years of experience in the financial industry, holding senior financial positions at multiple publicly traded and startup companies over a wide range of industries such as medical, telecommunications, device technology, digital arts, mobile devices, and internet technology. Before joining Vita Imaging, Dzung was Sr. Accounting Manager at Vivus, Inc. from 2013 to 2022 where she was Responsible for overseeing the corporate accounting team for a publicly traded pharmaceutical company. She has also held senior finance roles at Controlnet Inc., Foneweb Inc., and Microlambda Wireless Inc. She has a proven track record of success in leading and managing financial teams, and she has a deep understanding of financial reporting, analysis, and planning. Dzung is a graduate of San Jose State University and holds a Bachelor’s degree in Business Administration and Accounting.

Maria Victoria Reade
COO

Ms. Reade has 25+ years of executive leadership and consulting experience including: Executive Director, MCO Operations & MSO at Scripps Clinic & Green Hospital La Jolla; VP, Medical Management at HMO Pacificare, Healthcare/IT Consultant at Deloitte, TMI, Pharma & Medtech. Previously, she was the Founder and CEO of Ion Therapeutics, a medical device & biologics company where she successfully secured FDA device approval; served as CEO & Chief Administrative Officer (CAO) of College Medical Center (157 bed hospital); Site Director, Quest Clinical Research conducting Pivotal Studies; and Research Leader of UCSD & Schepens Institute/Harvard teams. Ms. Reade holds an MBA from Pace University and a Bachelor of Science Nursing (BSN) from the University of Tennessee Center for Health Sciences. She is an Advisor for Business and Academic Accelerator Programs (California Life Sciences Institute & Hult Global Business Challenge).

Names and titles as disclosed on SEC Form C, StartEngine. Bios and photos come from the platform campaign page and may be out of date.

Reg CF annual-report compliance

Not required3+ reports filed & assets ≤ $10M

Filed 3 of 3 annual reports (FY2023–FY2025)

582 investors
holder-count proxy

Reg CF issuers must file a Form C-AR each year until a Rule 202(b) termination trigger is met.

  • Form C-WOct 2, 20260001804181-26-000005
    EDGAR
  • Form C/AJul 13, 20260001804181-26-000003
    EDGAR
  • Form CJul 10, 20260001804181-26-000002
    EDGAR
  • Form C-ARJul 9, 20260001099910-26-000235
    EDGAR
  • Form C-UFeb 5, 20260001804181-26-000001
    EDGAR
  • Form C/ADec 12, 20250001804181-25-000004
    EDGAR
  • Form C/AOct 16, 20250001804181-25-000003
    EDGAR
  • Form CJul 23, 20250001665160-25-001320
    EDGAR
Source: ManualCIK 0001804181DEShare price $5.70

About this data. Figures are compiled from public sources — SEC EDGAR filings (Form C, C-AR, 1-A, 1-K) and funding-platform pages — and may be delayed, incomplete, or restated by the issuer. Financial statements are as reported by the issuer; each year is labeled with its assurance level (audited / reviewed / unaudited). A valuation cap is the conversion ceiling of a SAFE or convertible note, not an agreed company valuation; post-money figures are computed as pre-money plus amount raised and are not a traded price. Crowdonomics is not a broker-dealer, funding portal, or investment adviser; nothing here is investment advice or an offer to sell securities. Verify all figures against the linked EDGAR filings.